HSBC Holdings’s Relmada Therapeutics RLMD Stock Holding History

HSBC Holdings’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,275	Closed	-$247K	–	3413
2022 Q1	$247K	Buy	+9,275	New	+$192K	﹤0.01%	2882

Other funds holding RLMD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HSBC Holdings's RLMD Position: Q2 2022 in Review

HSBC Holdings sold out of Relmada Therapeutics (RLMD) in Q2 2022, closing a stake of 9,275 shares — an estimated $247K sold.

HSBC Holdings first reported a position in RLMD in Q1 2022 and held it in 1 quarter. The position peaked at $247K in Q1 2022. 113 funds tracked by Wall St. Rank hold RLMD as of Q2 2022.

HSBC Holdings reported no remaining Relmada Therapeutics position as of Q2 2022 after selling out during the quarter.
HSBC Holdings sold 9,275 Relmada Therapeutics shares in Q2 2022, an estimated $247K.
HSBC Holdings first reported a position in Relmada Therapeutics in Q1 2022 and held it in 1 quarter.
HSBC Holdings's Relmada Therapeutics position peaked at $247K in Q1 2022.
113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2022.

Based on HSBC Holdings's 13F filing for Q2 2022, filed 11 Aug 2022.